Sieg A, Brenner H
Praxis für Gastroenterologie, Universität Heidelberg, Heidelberg, Germany.
Z Gastroenterol. 2007 Sep;45(9):945-51. doi: 10.1055/s-2007-963435.
Screening colonoscopy was introduced into the National Cancer Prevention Program in Germany in 2002. We have explored costs and savings of screening and surveillance colonoscopy to investigate whether the induced savings may compensate for the costs of screening.
The study design was a model calculation based on data of a large-scale documentation of screening colonoscopy. The costs and savings of screening colonoscopy were evaluated over a defined period of 10 years. Basic data about findings, adverse effects and costs of screening colonoscopy were obtained from a large-scale online registry of 109 989 procedures and from the actual payments of procedures in Germany. Plausible baseline parameter values of the characteristics of screening and surveillance colonoscopy, of adenoma progression and recurrence, and of costs for diagnosis and treatment of colorectal cancer were based on available data. The impact of major model assumptions was evaluated by sensitivity analyses.
A programme based on one-time screening colonoscopy could result in net savings over a period of 10 years in Germany due to avoidance of cancer treatment costs compensating for the costs of screening, surveillance and adverse effects. Average net savings from euro 121 to euro 623 per screenee could be achieved according to our model assuming different progression and recurrence rates of adenomas and carcinoma costs from euro 21 820 to euro 40 000.
For some major model parameters assumptions had to be derived from the literature.
This analysis based on empirical data from the nationwide screening colonoscopy programme in Germany suggests net savings resulting from colorectal cancer prevention that compensate for the costs of screening and surveillance.
2002年,结肠镜筛查被纳入德国国家癌症预防计划。我们探讨了结肠镜筛查及监测的成本与节省情况,以研究节省的费用是否能抵消筛查成本。
本研究设计是基于大规模结肠镜筛查记录数据的模型计算。在规定的10年期间评估结肠镜筛查的成本与节省情况。关于结肠镜筛查的检查结果、不良反应及成本的基础数据,来自一个包含109989例检查的大规模在线登记系统以及德国检查的实际付费情况。基于现有数据,设定了结肠镜筛查及监测特征、腺瘤进展与复发以及结直肠癌诊断和治疗成本等合理的基线参数值。通过敏感性分析评估主要模型假设的影响。
在德国,基于一次性结肠镜筛查的项目在10年期间可能会产生净节省,这是因为避免了癌症治疗成本,抵消了筛查、监测及不良反应的成本。根据我们的模型,假设腺瘤和癌的不同进展及复发率以及癌症成本从21820欧元到40000欧元,每位受检者平均可实现121欧元至623欧元的净节省。
对于一些主要模型参数,必须从文献中推导假设。
基于德国全国性结肠镜筛查项目的实证数据进行的这项分析表明,预防结直肠癌可带来净节省,足以抵消筛查和监测的成本。